Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Complement C3b Inactivator Proteins
Endogenous proteins that inhibit or inactivate COMPLEMENT C3B. They include COMPLEMENT FACTOR H and COMPLEMENT FACTOR I (C3b/C4b inactivator). They cleave or promote the cleavage of C3b into inactive fragments, and thus are important in the down-regulation of COMPLEMENT ACTIVATION and its cytolytic sequence.
Year introduced: 2006 (1978)
Complement C1 Inactivator Proteins
Serum proteins that inhibit, antagonize, or inactivate COMPLEMENT C1 or its subunits.
Complement Inactivator Proteins
Serum proteins that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host. The complement system is tightly regulated by inactivators that accelerate the decay of intermediates and certain cell surface receptors.
Complement Factor I
A plasma serine proteinase that cleaves the alpha-chains of C3b and C4b in the presence of the cofactors COMPLEMENT FACTOR H and C4-binding protein, respectively. It is a 66-kDa glycoprotein that converts C3b to inactivated C3b (iC3b) followed by the release of two fragments, C3c (150-kDa) and C3dg (41-kDa). It was formerly called KAF, C3bINF, or enzyme 3b inactivator.
Year introduced: 1993
Complement C4b-Binding Protein
A serum protein that regulates the CLASSICAL COMPLEMENT ACTIVATION PATHWAY. It binds as a cofactor to COMPLEMENT FACTOR I which then hydrolyzes the COMPLEMENT C4B in the CLASSICAL PATHWAY C3 CONVERTASE (C4bC2a).
Year introduced: 2006
Aprotinin
A single-chain polypeptide derived from bovine tissues consisting of 58 amino-acid residues. It is an inhibitor of proteolytic enzymes including CHYMOTRYPSIN; KALLIKREIN; PLASMIN; and TRYPSIN. It is used in the treatment of HEMORRHAGE associated with raised plasma concentrations of plasmin. It is also used to reduce blood loss and transfusion requirements in patients at high risk of major blood loss during and following open heart surgery with EXTRACORPOREAL CIRCULATION. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
Year introduced: 1990
Lysine Carboxypeptidase
A metallocarboxypeptidase that removes C-terminal basic amino acid from peptides and proteins, with preference shown for lysine over arginine. It is a plasma zinc enzyme that inactivates bradykinin and anaphylatoxins.
Year introduced: 1997 (1975)
Complement Factor I Deficiency [Supplementary Concept]
Date introduced: August 24, 2012
complement C5a-inhibitors [Supplementary Concept]
found in normal peritoneal & synovial fluids; deficiency causes familial Mediterranean fever; also found in Streptococcus; have capability of inactivating complement-derived chemotactic factors; do not use /antag
Date introduced: July 30, 1984
alpha-2-Antiplasmin
A member of the serpin superfamily found in plasma that inhibits the lysis of fibrin clots which are induced by plasminogen activator. It is a glycoprotein, molecular weight approximately 70,000 that migrates in the alpha 2 region in immunoelectrophoresis. It is the principal plasmin inactivator in blood, rapidly forming a very stable complex with plasmin.
Year introduced: 2010(1980)
Allylisopropylacetamide
An allylic compound that acts as a suicide inactivator of CYTOCHROME P450 by covalently binding to its heme moiety or surrounding protein.
Year introduced: 1991(1973)
N-(pyridine-3-ylmethyl)-5-(7-hydroxy-2,6,8-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-yl)-2-methylpenta-2,4-dienamide [Supplementary Concept]
an ADP-ribosylation factor 1 inactivator; has antineoplastic and angiogenesis inhibitory activity; structure in first source
Date introduced: July 29, 2012
cyclobranol [Supplementary Concept]
an analog of the cycloartenol; a substrate for C25-methyl sterol side chains and potent mechanism-based inactivator of plant sterol methyltransferase; structure in first source
Date introduced: November 13, 2008
4-(2-((4-methoxy-1H-indole-2-carbonyl)amino)-4-methylpentanoylamino)-5-(2-oxopyrrolidin-3-yl)pent-2-enoic acid ethyl ester [Supplementary Concept]
a 3CL(pro) inactivator; structure in first source
Date introduced: May 1, 2008
Rasa4 protein, mouse [Supplementary Concept]
GenBank AK133565
Date introduced: November 3, 2005
1,5-diamino-2-pentyne [Supplementary Concept]
substrate and inactivator of copper amine oxidases
Date introduced: July 3, 2005
CFI protein, human [Supplementary Concept]
RefSeq NM_000204
Date introduced: December 3, 2004
RASA4 protein, human [Supplementary Concept]
RefSeq NM_006989
Date introduced: September 29, 2004
1,2-dihydro-1-(chloromethyl)-5-hydroxy-8-methyl-3H-furano(3,2-e)indole [Supplementary Concept]
a (chloromethyl)furanoindoline (CFI); do not confuse with chemotactic factor inactivator
Date introduced: February 25, 1994
4-(fluoromethyl)phenyl phosphate [Supplementary Concept]
can function as a mechanism-based phosphotyrosine phosphatase inactivator and represents a useful paradigm for the design of potent & specific phosphatase inhibitors; structure given in first source
Date introduced: December 21, 1993